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Abstract There is a strong body of evidence that supports
the use of non-drug therapies in the management of people
with multiple sclerosis (MS). A 5-day residential retreat for
people with MS in Victoria, Australia, promotes lifestyle
modification within a patient-centred model of care.
Analysis of the health-related quality of life (HRQOL) of
the retreat participants was undertaken using the MSQOL-
54, prior to attendance, 1 and 5 years after the retreat. 274
retreat participants (71%) completed baseline question-
naires. Despite the usually progressive nature of MS, the
cohort demonstrated clinically and statistically significant
improvements in HRQOL. One year after attending the
retreat, median improvements of 11.3% were observed in
the overall quality of life domain (p \ 0.001); 18.6% in the
physical health composite (p \ 0.001); and 11.8% in the
mental health composite (p \ 0.001). In the subset of 165
who had reached the 5-year time-point, there was a 19.5%
median improvement in overall quality of life (p \ 0.001);
17.8% in the physical health composite (p \ 0.001) and
22.8% in the mental health composite (p \ 0.001), com-
pared to baseline. Attendance at a retreat promoting life-
style modification for the integrated management of MS
appears to have positive effects on short and medium-term
HRQOL. Non-drug therapies should be considered as part
of any comprehensive treatment plan for people with MS.
Keywords Quality of life  MSQOL-54 
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Introduction
Multiple sclerosis (MS) is the most common progressive
neurological disorder affecting young adults [1]. Women
are twice as likely as men to be affected with MS, with an
estimated incidence rate of 3.6 per 100,000 [2], varying
considerably with geographic region. MS is thought to be
immune-mediated, however, despite decades of research,
the aetiology and factors that trigger relapses and influence
disease progression continue to be debated [3]. Disease
activity and clinical course are unpredictable, usually
resulting in a broad range of symptoms and functional
limitations, with depression and fatigue the most common
[4]. Many patients report feelings of hopelessness and
uncertainty, particularly if they are not actively engaged in
decision-making about their care [5]. Additionally, MS can
have a major impact on families due to increased role
responsibilities, social isolation, employment challenges
and financial hardship.
Current treatment options for MS focus mainly on
pharmaceutical intervention. First line immune-modulating
drugs such as beta interferon and glatiramer acetate reduce
relapse rates by around 30%, show MRI evidence of
reducing disease activity, and can help preserve cognition;
however there remain concerns regarding the short- and
long-term side effects of such drugs and whether they make
a real difference to the progression of the illness [6–8].
Nonetheless, observational studies have suggested that the
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disease-modifying treatments may have increased the sur-
vival, with somewhat slower accumulation of disability,
raising the possibility of a new natural history of the illness
[9]. This may, however, to some extent reflect increased
recognition of MS with better diagnostic techniques [9].
Comprehensive literature also exists examining the
relationship between modifiable lifestyle and psychosocial
factors and MS progression [10]. However, most clinicians
adopt a drug-only approach to disease modification, despite
calls for a more integrated approach [11].
Consumer demand for non-drug intervention is evident
through the large proportion of people with MS using
complementary and alternative medicines in addition to
mainstream medical treatment [12]. Likewise, wellness
programmes provide a supportive, informative environ-
ment well-suited to assist individuals in self-managing
their diverse symptomatology. Despite this, there is limited
literature evaluating the effectiveness of this type of
approach to MS management. Two systematic reviews [13,
14] of wellness programmes discuss the importance of
patient-centred, multidisciplinary approaches in the man-
agement of chronic illness. Both studies found that despite
the reported benefit of wellness programmes, the existing
literature is deficient and mainly consists of only short-term
follow-up.
A live-in educational programme at The Gawler Foun-
dation in Victoria, Australia, provided a unique opportunity
to assess the impact of such modifiable lifestyle factors on
MS outcomes. Due to the unpredictable nature of the ill-
ness, is it important to evaluate MS outcomes in the
medium to long-term. To date, apart from our published
findings of health-related quality of life (HRQOL) out-
comes at one and two-and-a-half years after attending this
programme [15], there have been no other studies exam-
ining the effect of a multimodal residential programme
promoting lifestyle modification for people with MS. As
we have continued to collect follow-up data from this
cohort, we aimed to present results of analyses of the
cohort at the 1 and 5 year marks post-retreat.
Materials and methods
Programme
Since April 2002, a 5-day live-in programme for people
with MS has been operating two to three times a year at
The Gawler Foundation in the Yarra Valley in Victoria,
Australia. Funded by donations and course fees, this not-
for-profit organisation is experienced with operating inte-
grated wellness programmes for people living with chronic
illness and can accommodate up to 36 people, including
partners and carers of people with MS. The only other
comparable programme is offered by the MS Society of
Auckland and the North Shore in New Zealand, facilitated
by one of the authors [16]. The MS programme has been
designed in accordance with the available literature that
supports the integrated management of MS with: a low-fat,
plant-based diet; exercise; sunlight exposure; vitamin D
and omega-3 supplementation; and meditation and stress
reduction techniques (Box 1). The evidence supporting the
programme interventions has been discussed elsewhere
[10, 11, 15, 17–19]. In addition to provide evidence-based
education about lifestyle modification, participants engage
in daily meditation, group and individual counselling,
gentle exercise, yoga and Qigong. The programme is
taught in a dynamic, interactive way which allows the
participants to share their experiences and ask questions.
Beyond the programme, the facilitators encourage partici-
pants to develop the various modalities into an ongoing
treatment regime with medical oversight by their usual
healthcare providers.
Box 1 Retreat recommendations (adapted from Li et al. [15])
Diet and supplements
Plant-based wholefood diet plus fish; minimal saturated fat
Omega-3 fatty acid supplements: 20 g a day (flaxseed or fish oil)
Vitamin D
Sunlight 15 min daily 3–5 times a week
Vitamin D3 5,000 IU daily




30 min 5 times a week
Medication
One of the disease-modifying drugs, beginning early in the
illness if possible, if required
Steroids for any distressing acute relapse
Methods
Participants who enrolled in a MS retreat at The Gawler
Foundation were invited to take part. In order to attend the
retreat, participants must be over 18 years of age and speak
English proficiently. Anyone who self-reported being
diagnosed with MS by a neurologist was eligible for the
study. Those providing consent completed a validated
questionnaire, the Multiple Sclerosis Quality Of Life
(MSQOL-54) [20], prior to attending the retreat, and again
at 1-, 2.5- and 5-year time-points. The 2.5-year time-point
was phased out in 2009 to reduce the burden of compli-
ance. A funded research officer commenced oversight of
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the dataset in 2008. The research officer attempted to locate
participants who had changed address and actively sought
responses from participants. An online questionnaire was
offered to participants for baseline and follow-up in addi-
tion to the existing paper-based version in February 2009.
Only those who completed a baseline were invited to
continue participation. In the early phase of the study
clerical issues meant that some groups did not receive an
invitation to participate at the 1-year time-point.
Ethics
A detailed explanation of the research was given to all
participants at every time-point and formal, written consent
was obtained. It was emphasised that a decision to decline
participation would not affect their experience or interac-
tions with staff at The Gawler Foundation. Approval to
conduct this study was granted by the Human Research
Ethics Committee of the University of Melbourne (HREC
ID: 0723028.1). All survey data were subjected to confi-
dentiality and patient codes were only re-identified for the
purpose of contacting participants for follow-up.
Evaluation tool
Evaluation of the programme at the time-points was
facilitated by patient self-report using the MSQOL-54,
which has been adapted from the RAND 36-item health
survey and has demonstrated sound psychometric proper-
ties [20]. Since the introduction of the MSQOL-54 in 1995,
it has been widely used as an outcome measure and has
been culturally and linguistically adapted for the purpose of
international research [21–24]. In addition to the core
health survey questions, the MSQOL-54 has been supple-
mented to include measures of health distress, sexual
function, energy, pain and social function, thus giving rise
to 14 scales. Table 1 shows the weighted sum of selected
domains which determine physical and mental health
composite scores. Like the individual scale scores, the
composite scores range from 0 to 100, with higher scores
indicating a better health outcome.
Statistical analysis
As the data were not normally distributed (Kolmogorov–
Smirnov statistic), the Friedman’s test and Wilcoxon
Signed Ranks test were used to make comparisons between
baseline, 1- and 5-year time-points and the Mann–Whitney
U test to compare the cohort with those lost to follow-up.
Medians were used as summary statistics. The evaluation
of the 2.5-year surveys was published elsewhere [15] and
as no new data were available for this time point, it was
excluded from analysis. The time-points were assessed
separately as few participants completed all three surveys.
Prior to analysis of the data, the level of significance was
defined as p \ 0.05. All statistical analyses were carried
out with PASW 18.0 software.
Results
Participation rates
A total of 394 participants attended a retreat for MS at The
Gawler Foundation between April 2002 and August 2010.
Seven were excluded from the study as they were not
formally diagnosed with MS or had another neurological
condition. All 387 eligible participants completed the full
5-day programme. Of those eligible to participate, 274
(71%) completed a baseline questionnaire, of whom 227
(83%) were female. Due to the predominant representation
of women in the cohort, gender comparisons were not
made. The smaller subset of participants who completed
5-year surveys is due to the limited number (n = 165) who
had completed a baseline questionnaire and reached the
5-year time-point. A smaller number of people completed
surveys at all three time-points (n = 47).
Participation rates vary between domains as they have
been adjusted according to the scoring criteria set by
Vickrey 1995 [20], which requires a minimum number of
items to be completed to give rise to a domain score.
Accordingly, there is variation in the response rates for
individual domains at each time-point. Baseline overall
quality of life was compared between those who only
completed baseline and were subsequently lost to follow-
up and those who completed baseline and at least one other
time-point. There was no statistically significant difference
in the physical health composite (p = 0.414) or mental
health composite (p = 0.131) between these two groups
when compared using the Mann–Whitney U test.
Table 1 Weighted sum of MSQOL 54 domains
Physical health composite Mental health composite
Domains Weight Domains Weight
Physical function 0.17 Health distress 0.14
Health perceptions 0.17 Overall quality of life 0.18
Energy/fatigue 0.12 Emotional well-being 0.29
Role limitations due to
physical problems
0.12 Role limitations due to
emotional problems
0.24
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Domain rank comparison baseline, 1 and 5 years
The Friedman test was conducted to compare results for
each domain at all three time-points and detected signifi-
cant differences in 9 of 14 domain scores and both mental
and physical health composites (Table 2). As only 47
participants had completed surveys at all time-points,
separate post hoc tests were run to compare baseline to
1-year results and baseline to 5-year results, which repre-
sented a larger proportion of the cohort.
1-year time-point
Of the 270 participants sent invitations at the 1-year time-
point, surveys were completed by 196 participants, for a
73% response rate. At 1 year, 13 of 14 domains and both
composite scores showed positive median changes, dem-
onstrating improvements in HRQOL. The median changes
were significantly different from zero in 11 of these 13
domains and both physical and mental health composite
scores. No change in median score was observed in role
limitations due to emotional problems, although the Wil-
coxon Signed Ranks test detected a significant difference
(p = 0.002). Improvements for physical health and sexual
function were not statistically significant. The greatest
change over time was seen in the domains: role limitations
due to physical problems; change in health; and satisfaction
with sexual function. They all demonstrated a 50% (25
point) improvement 1 year after baseline. The smallest
statistically significant improvement was observed for
cognitive function, which increased by five points. At
1 year overall quality of life improved 11.3% (p \ 0.001),
physical health composite 18.6% (p \ 0.001) and mental
health composite 11.8% (p \ 0.001) (Table 3; Fig. 1).
5-year time-point
Similar changes were detected at the five year time-point
(Table 4). Of those reaching the 5-year time-point
(n = 165), surveys were completed by 96 participants, for a
58% response rate. Improvements were observed in 11 of the
14 MSQOL domains, of which nine were statistically sig-
nificant. Three domains detected no change over time
including change in health, sexual function and satisfaction
with sexual function. The latter two domains were not sta-
tistically significant, nor were physical health or pain scale
scores. Akin to 1 year, despite no median change over time,
significant differences were still detected by the Wilcoxon
Signed Ranks test for change in health (p = 0.009). The
biggest improvements after 5 years were observed in role
limitations due to physical problems with a 37.5 point
increase (100% median difference; p = 0.001), followed by
a 17.5-point median improvement in health distress
(p \ 0.001). Both the mental health and physical health
composites were statistically significant and improved over
time with a percentage median difference of 22.8 and 17.8%
respectively, over 5 years, with an overall improvement in
quality of life of 19.5% (p \ 0.001) (Table 4; Fig. 1).
Discussion
Our study, the first of its kind, indicates a significant per-
sistent improvement in short- and medium-term HRQOL
Table 2 Comparison of mean
ranks at baseline, one year and
five year time points
Differences assessed using
Friedman test
n Number of participants
Domain scores and composite scores n Mean rank Chi-square p value
Baseline 1 year 5 year
Physical function 47 1.89 2.13 1.98 1.653 0.438
Role limitations-physical 46 1.74 2.18 2.08 8.309 0.016
Role limitations-emotional 43 1.73 2.12 2.15 11.400 0.003
Pain 46 1.97 2.13 1.90 1.708 0.426
Emotional well-being 47 1.61 1.94 2.46 19.602 0.000
Energy 47 1.60 2.24 2.16 12.489 0.002
Health perceptions 46 1.55 2.08 2.37 17.815 0.000
Social function 43 1.77 2.01 2.22 5.729 0.057
Cognitive function 47 1.74 2.24 2.01 7.789 0.020
Health distress 45 1.44 2.23 2.32 23.346 0.000
Sexual function 42 2.11 2.05 1.85 1.942 0.379
Overall quality of life 47 1.51 2.18 2.31 20.808 0.000
Change in health 45 1.76 2.37 1.88 14.356 0.001
Satisfaction with sexual function 41 1.87 2.23 1.90 4.748 0.093
Physical health composite 37 1.57 2.30 2.14 10.865 0.004
Mental health composite 41 1.54 2.20 2.27 13.317 0.001
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for people with MS after attending a live-in educational
retreat. 1 and 5 years after attendance, most of the
MSQOL-54 domains demonstrated significant improve-
ments, with no domain detecting a decline in self-reported
HRQOL. This applied to both mental and physical health
composites, which continued to improve over the 5-year
time frame. As MS is known to result in deteriorating
quality of life and increasing disability over time, these
results are remarkable.
MS can have a profound impact on a person’s quality of
life and in the absence of a cure, maintenance of function
and quality of life are the focus of treatment. Clinical
outcome measures of relapse rate and disability are insuf-
ficient alone to assess the impact of disease, thus a more
broad measurement tool is required [25, 26]. HRQOL is a
multifaceted concept that incorporates the symptom-related
impact of disease as well as psychosocial aspects such as
fatigue, emotional well-being or participation [27]. A
quality of life tool can be used to assess health disparities
within a population or the effectiveness of interventions.
Self-reported data in MS cohorts have been found to be a
reliable measure of patient outcomes [28, 29]. In our study,
due to the varied level of participant disability, both
hardcopy and online questionnaire formats were offered to
ease facilitation of survey completion. The online format
was found to be the preferred method of most participants.
The mental health composite scores demonstrated clin-
ically and statistically significant improvements at both 1
and 5-year time points. This is important because preva-
lence rates of depression and anxiety are high in patients
with MS and can affect the way a patient copes with the
limitations of the disease [30]. Social isolation and a lack
of social support can further exacerbate psychological
decline, leading to poorer quality of life [30, 31]. ‘‘Invisi-
ble’’ symptoms of MS (depression, anxiety, fatigue and
Table 3 Comparison of domain and composite scores at baseline and 1-year time-points




Z score p value
Median (IQR)
Physical health 190 75.0 (40.0–90.0) 80.0 (45.0–95.0) 5.0 6.7 -1.401 0.161
Role limitations-physical 194 50.0 (0.0–100.0) 75.00 (0.00–100.00) 25.0 50.0 -3.791 \0.001
Role limitations- emotional 185 100.0 (33.3–100.0) 100.0 (66.7–100.0) 0.0 0.0 -3.108 0.002
Pain 190 85.8 (70.0–100.0) 93.3 (76.7–100.0) 7.5 8.7 -3.044 0.002
Emotional well-being 196 72.0 (60.0–84.0) 80.0 (68.0–88.0) 8.0 11.1 -4.696 \0.001
Energy 196 48.0 (32.0–67.0) 60.0 (40.0–72.0) 12.0 25.0 -4.658 \0.001
Health perceptions 191 60.0 (45.0–75.0) 70.0 (55.0–85.0) 10.0 16.7 -5.658 \0.001
Social function 183 75.0 (58.3–91.7) 83.3 (66.7–91.7) 8.3 11.1 -3.319 0.001
Cognitive function 190 80.0 (60.0–90.0) 85.0 (65.0–95.0) 5.0 6.3 -3.603 \0.001
Health distress 190 62.5 (43.8–80.0) 80.0 (60.0–90.0) 17.5 28.0 -7.446 \0.001
Sexual function 166 79.2 (58.4–91.7) 83.4 (58.3–100.0) 4.2 5.3 -0.590 0.555
Overall quality of life 195 73.4 (60.0–81.7) 81.7 (68.4–86.7) 8.3 11.3 -5.433 \0.001
Change in health 194 50.0 (25.0–50.0) 75.0 (50.0–75.0) 25.0 50.0 -7.017 \0.001
Satisfaction with sexual function 168 50.0 (25.0–75.0) 75.0 (50.0–100.0) 25.0 50.0 -2.130 0.033
Physical health composite 149 63.7 (48.6–77.8) 75.50 (56.4–84.9) 11.8 18.6 -5.408 \0.001
Mental health composite 178 72.9 (51.9–85.1) 81.5 (68.7–90.3) 8.6 11.8 -5.697 \0.001
Differences analysed using Wilcoxon Signed Rank test
n Number of participants, IQR interquartile range
Fig. 1 Percentage change in median MSQOL-54 composite and
overall quality of life scores at baseline, 1 and 5 years after a
residential retreat. *All differences represent significant improvement
(p \ 0.001) from baseline
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pain) can be more difficult to assess clinically but are
thought to have a greater impact on health distress [32].
More concerning, is evidence demonstrating the effect that
poor psychological health can have on disease progression.
A meta-analysis [33] of the relationship between stressful
life events and MS exacerbations found a clinically
meaningful effect size. This supports earlier work showing
an increased risk of brain lesions 8 weeks after the
occurrence of stress, with preoccupation and coping as
moderators of this effect [34]. The stress reduction tech-
niques and meditation taught at the retreats may assist
participants in coping with high levels of stress and drive
the considerable improvements in the mental health com-
posite scores. Such interventions can easily be incorporated
into a management plan for dealing with adjustment issues
and stress and may also slow disease progression.
People with MS constitute a heterogeneous group with
diverse needs and modes of adaptation in coping with the
limitations of the illness [35]. In contrast with physicians,
people with MS may view physical disability as less
important than other quality of life dimensions such as
emotional well-being and vitality [36]. The process of
patient-centred care involves engaging individuals and
encouraging them to share in the decision-making role to
create a disease management plan that incorporates their
physical, psychological and socio-cultural needs [37].
Shifting the paradigm of MS care to a patient-centred
approach has the potential to improve patient outcomes and
satisfaction with the provider’s service [5]. It is thought
that mastery, or the degree to which people feel they are in
control of their illness, plays an important role in health
status. Patients with higher levels of self-efficacy and
empowerment report lower rates of depression [38] and are
more likely to effectively self manage their illness through
the appropriate utilisation of services and treatment
adherence [39]. The facilitators have recognised tailoring
patient-centred care and fostering empowerment as
important approaches in the design and operation of our
MS programme. This might help explain why patients
report lower rates of health distress and improved emo-
tional well-being 5 years after the retreat.
Despite improvements in the sexual health domains at
the 1-year time-point, no change was observed at 5 years.
Sexual dysfunction is common in MS with 40–85% of
women and 50–90% of men being adversely affected [40].
One study found a significant negative correlation between
sexual dysfunction and nearly all MSQOL-54 domains
[41]. It presents a significant burden for self-esteem and
relationships but unfortunately, this problem is insuffi-
ciently addressed by both the person with MS and the
physician who are often reluctant to discuss it [42].
Although there was no worsening of sexual function, per-
haps the programme could be adapted to more openly
discuss some of the potential solutions to this prevailing
issue. Pain is also a difficult management issue, with no
really effective pharmacological agents available, and no
Table 4 Comparison of domain and composite scores at baseline and 5-year time-points




Z score p value
Median (IQR)
Physical health 96 75.0 (46.3–95.0) 82.5 (40.0–95.0) 7.5 10.0 -1.122 0.262
Role limitations-physical 96 37.5 (0.0–100.0) 75.0 (6.3–100.0) 37.5 100.0 -3.921 \0.001
Role limitations-emotional 92 83.3 (0.0–100.0) 100.0 (66.7–100.0) 16.7 20.0 -3.967 \0.001
Pain 95 85.0 (70.00–100.00) 93.33 (71.7–00.0) 8.3 9.8 -0.669 0.503
Emotional well-being 96 72.0 (56.0–84.0) 80.0 (68.0–88.0) 8.0 11.1 -4.328 \0.001
Energy 96 48.0 (29.0–64.0) 56.0 (40.0–72.0) 8.0 16.7 -3.735 \0.001
Health perceptions 95 60.0 (45.0–75.0) 75.0 (55.0–85.0) 15.0 25.0 -4.334 \0.001
Social function 90 75.0 (58.3–91.7) 83.3 (66.7–100.0) 8.3 11.1 -2.875 0.004
Cognitive function 96 80.0 (56.3–90.0) 85.0 (65.0–95.0) 5.0 6.3 -2.023 0.043
Health distress 94 62.5 (35.0-80.0) 80.0 (63.8–95.0) 17.5 28.0 -6.100 \0.001
Sexual function 84 75.0 (58.3–91.7) 75.0 (50.0-91.7) 0.0 0.0 -0.167 0.868
Overall QOL 95 68.4 (58.4–81.7) 81.7 (63.4–90.0) 13.3 19.5 -3.603 \0.001
Change in health 94 50.0 (25.0–50.0) 50.0 (50.0–75.0) 0.0 0.0 -2.599 0.009
Satisfaction with sexual function 87 50.0 (25.0–75.0) 50.0 (25.0–75.0) 0.0 0.0 -0.417 0.667
Physical health composite 78 64.5 (47.4–78.4) 75.9 (56.8–87.7) 11.4 17.8 -3.887 \0.001
Mental health composite 89 67.4 (50.2–85.1) 82.8 (72.1–90.1) 15.4 22.8 -4.924 \0.001
Differences analysed using Wilcoxon Signed Rank test
n Number of participants, IQR interquartile range
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significant change in pain detected at the 5-year point
following our programme.
The global improvements in health status observed over
the 5-year period are considerably better than one would
expect, given the usually progressive, degenerative nature
of the illness. While it is difficult to make comparisons
with other studies as few have observed patients for more
than 2 years, in general, studies measuring HRQOL over
time report a predominant decline in the health status of the
participants [43–46]. One study [45], which measured
MSQOL-54 over a 5-year period documented no change,
or a worsening in 11 of the 14 health domains. This con-
trasts dramatically with our study. A wellness programme
for women in the United States [47] saw some improve-
ments in pain and mental health scales, however, the fol-
low-up concluded only 8-months after the intervention.
Limitations
A longitudinal cohort study is the appropriate method to
assess outcomes in MS, which is usually progressive and
varies for individuals over time. The absence of a control
group, and declining response rates over time, however,
decrease the strength of the evidence. With more than half
the participants returning 5-year follow-up data, and no
domain worsening over that period, it is unlikely, however,
that we are simply observing a benign MS group, who are
thought to comprise only a small fraction of people with
MS, and whose quality of life and function are documented
to deteriorate over time [48].
It is difficult to know which aspects of the programme
had the greatest impact on self-reported quality of life. The
favourable results could be viewed as being related to the
participants’ altered perception of quality of life over time,
as opposed to a tangible change, or that they simply learned
to cope with the limitations of the disease. This is unlikely
though, because most studies have shown deterioration in
HRQOL over time using the MSQOL-54. Additionally,
there may have been participation bias, although there is no
clear reason why those not providing consent to participate
would have had a different course than those participating.
Similarly, the follow-up results may, in part, be attributed
to responder bias. However, comparison of the baseline
overall quality of life domain showed no significant dif-
ference between participants who only completed a base-
line questionnaire and those who continued to contribute
data at the 1 or 5 year time-points.
We do not currently know the degree to which partici-
pants adhered to each individual lifestyle intervention long-
term. Future research on this cohort will include measures
of programme adherence. Additionally, it is unknown to
what degree pharmaceutical intervention had an impact on
quality of life, both in terms of reduced relapse rates and
worsening of HRQOL due to side effects. We can, how-
ever, anecdotally report that many of the participants were
not taking immune-modulating therapies.
MS diagnosis was self-reported by participants. The few
people reporting neurological disorders other than MS were
permitted to take part in the programme but excluded from
analysis. Additionally, it is unknown which type of MS the
participants had been diagnosed with and whether they
were representative of the average distribution in the gen-
eral MS population.
Conclusion
This study adds to the evidence supporting the use of
integrated non-drug therapies for people with MS. Lifestyle
modification should form part of any comprehensive
chronic disease management plan, and given that there are
likely to be other health benefits associated with this
approach, there is considerable merit in offering this to
people with MS. In addition to the benefits patients should
experience, there are also likely to be reduced healthcare
costs and improved satisfaction with the health service. The
promotion of lifestyle intervention is not in competition
with the use of pharmacological therapies; both should be
considered for their potential benefits and risks, with
decisions tailored to the needs of the individual. Trials
assessing the impact of lifestyle modification long-term are
methodologically complex and there are fewer financial
incentives to invest in such research. Regardless, this study
adds to the evidence supporting the use of a range of
lifestyle interventions for people with MS.
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